Patient-reported outcome measures for use in patients with alpha-1-antitrypsin deficiency: results of a systematic selection process Authors: Karolina Müller, Louisa Vogl, Helge Knüttel, Timm Greulich, Frank Lammert, Pavel Strnad, Claus, Franz Vogelmeier, Marion Wilkens, Robert Bals, Michael Koller Published: 2025 ABSTRACT AbstractObjectiveAlpha-1-antitrypsin deficiency (AATD) is a hereditary condition associated with the risk of developing chronic lung and liver disease. We aimed for a patient-reported outcome measure (PROM) that addresses generic, lung-specific and liver-specific aspects of quality of life (QoL) in individuals with AATD. Rather than developing a new PROM, we evaluated existing PROMs.MethodAn extensive literature search and eligibility assessment, accompanied by standardised group processes including patient representatives, were conducted in accordance with the guidelines in this research area (COnsensus-based Standards for the selection of health Measurement INstruments, COSMIN; Preferred Reporting Items for Systematic Reviews and Meta-Analyses, Prisma; Peer Review of Electronic Search Strategies, PRESS).ResultsOver 1200 records were identified and screened. In total, 427 PROMs were obtained and assessed for eligibility. 15 of the 247 PROMs fulfilled the predefined eligibility criteria. The final selection of the three PROMs—EuroQoL 5 Dimension 5 Level (generic), COPD Assessment Test (lung-specific) and Chronic Liver Disease Quality of Life (liver-specific)—was guided by factors such as brevity, ease of use, interpretability, strong content validity, availability of minimal clinically important differences, sensitivity to change, ability to differentiate disease severity and availability of reference data. A questionnaire was assembled that incorporated the three selected PROMs, as well as additional QoL issues not covered by them, to ensure a comprehensive assessment of patient-reported outcomes.ConclusionThe PROM named Assessment of Lung, Liver and Patient Health in Alpha-1 (ALPHA) was designed to address generic, lung-specific as well as liver-specific QoL issues in patients with AATD. As a next step, the validity and feasibility in clinical practice of the designed questionnaire will be evaluated.PROSPERO registration numberCRD42021265360.Keywords: Alpha1 Antitrypsin Deficiency, Patient Outcome Assessment WHAT IS ALREADY KNOWN ON THIS TOPIC Up to now, there is no accepted and validated measurement approach addressing quality of life in patients with alpha-1-antitrypsin deficiency. Up to now, there is no accepted and validated measurement approach addressing quality of life in patients with alpha-1-antitrypsin deficiency. WHAT THIS STUDY ADDS We reviewed the current literature on patient-reported outcome measures for alpha-1-antitrypsin deficiency. Based on our findings, we propose a measure that covers generic, lung-specific and liver-specific aspects of quality of life in patients with this rare disease. We reviewed the current literature on patient-reported outcome measures for alpha-1-antitrypsin deficiency. Based on our findings, we propose a measure that covers generic, lung-specific and liver-specific aspects of quality of life in patients with this rare disease. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY Our work contributes to enhancing patient-centred assessment in alpha-1-antitrypsin deficiency and may support both clinical care and future research by promoting the standardisation in outcome measurement. Our work contributes to enhancing patient-centred assessment in alpha-1-antitrypsin deficiency and may support both clinical care and future research by promoting the standardisation in outcome measurement. Introduction Alpha-1-antitrypsin deficiency (AATD) is a hereditary condition that encompasses rare severe forms (such as the most common type Pi*ZZ) as well as mild genotypes (such as Pi*MZ).1 AATD is associated with an elevated risk of developing chronic obstructive pulmonary disease (COPD), emphysema, chronic liver disease, ANCA-positive vasculitis and panniculitis.1 2 The management of AATD primarily addresses lung and liver pathologies. Pulmonary manifestations present as an early-onset form of COPD and emphysema and are treated similarly to the non-deficient forms. Additionally, these patients may receive augmentation therapy with weekly infusions of purified AAT. At present, no specific drug has been approved for the treatment of liver disease associated with AATD. Awareness is growing that patient-reported outcomes (PROs) are a crucial element of both effective patient care and well-designed clinical studies.3 The umbrella term PRO relates to all types of outcomes that are directly reported by patients, such as quality of life (QoL), satisfaction with care, preferences or somatic symptoms.4 QoL is the most encompassing concept and is commonly defined as a multidimensional construct covering subjective well-being and behavioural capacities in the psychological, social and somatic domains.5 Patient-reported outcome measures (PROMs) were initially designed for clinical trials to evaluate treatment efficacy. Over time, their use has expanded into routine clinical practice, aiding clinical decision-making and treatment planning.6 It is widely agreed that assessing PROs is particularly valuable for individuals with chronic conditions. PROs enhance communication between patients and healthcare providers by offering information about symptoms, side effects and QoL. This ensures that patients feel better heard and understood. Consequently, the selection of appropriate PROMs is essential not only for clinical studies but also for everyday clinical care, to ensure relevance and utility in both contexts. The overall goal of this project was to survey the current state of PRO assessment in AATD patients to identify an appropriate assessment system and, subsequently, to test its feasibility and validity through a pair of studies to be conducted in specialised AATD centres across Germany. This paper presents the results of a systematic literature review and outlines the decision-making process for selecting the most appropriate PROMs. Method Overview The selection of PROMs requires a profound methodological approach.6 Therefore, the current project was conducted in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) statement on reporting systematic review protocols,7 the COSMIN (COnsensus-based Standards for the selection of health Measurement INstruments) initiative on systematic reviews of PROMs and selection of outcome measures,8 9 as well as additional guidelines in this research area.310,12 The study protocol was registered in PROSPERO (CRD42021265360), and the corresponding protocol was published.13 We searched for PROMs that were specifically developed for AATD patients as well as for PROMs used in the context of AATD studies. These PROMs might assess generic QoL or address symptoms and signs connected with the sequelae of AATD, in particular COPD or chronic liver disease. All identified instruments were rated against pre-defined eligibility criteria and content-based criteria defined by clinical experts. Our selection process focused on the content and clinical appropriateness of PROM candidates (which are the initial criteria according to COSMIN) rather than on their psychometric properties. Our project also included an empirical phase to investigate the feasibility and psychometric performance of the selected PROMs. Results will be addressed in upcoming publications. Defining selection criteria Basic eligibility criteria At the start of the project, the research group specified a set of eligibility criteria that the questionnaire should fulfil13: The questionnaire Is a PROM and assesses QoL. Is a PROM and assesses QoL. Is available in German. Is available in German. Is designed for adults. Is designed for adults. Is either specifically developed for AATD patients and/or covers generic aspects and/or disease-specific aspects for either lung or liver symptoms of AATD patients. Is either specifically developed for AATD patients and/or covers generic aspects and/or disease-specific aspects for either lung or liver symptoms of AATD patients. Covers a range of early and late disease symptoms seen in these patients. Covers a range of early and late disease symptoms seen in these patients. Is user-friendly, short and free of charge for academic use. Is user-friendly, short and free of charge for academic use. Defining contents from a clinical perspective Relevant QoL domains for AATD patients were defined in the context of a standardised group process.11 The group consisted of six experts (clinicians: RB, TG, CV, FL, PS, and representative of patient organisation: MW) with years of experience in treating or caring for AATD patients (range 6 years to 35 years). In preparation for the group process, two experts in QoL (KM and MK) prepared a list of 151 QoL issues that covered general QoL aspects (n=38), general symptoms (n=50), lung-specific symptoms (n=17) and liver-specific symptoms (n=46). This list was sent out to the six AATD experts, who independently rated each QoL issue on a 4-point Likert scale (0=not relevant, 1=less important, 2=important, 3=very important). Results of the survey were presented and consented to in a web-based group meeting. Table 1 summarises the outcome of the group consensus. Table 1Summary of relevant quality of life domains and aspects selected by expertsGeneral physical healthExercising activitiesSocial aspectsEmotional aspectsFear regarding liver problemsFear regarding lung problemsUnspecific symptomsSymptoms of fatigueOrgan specific symptomsPhysical fitnessActing independentlyRestrictions on family lifeWorries/fears about the futureConcern regarding availability of an organ in case of transplantationFear of dyspnoeaMuscle atrophyLoss of performanceCough in generalAssessment of the general state of healthPerforming strenuous/moderately strenuous/light activitiesFamily planningGeneral worriesFear of worsening of liver diseaseFear of oxygen dependenceSusceptibility to infectionsDecreased energyDry coughInvalidity (permanent)Limitation in everyday activitiesSocial isolationFear of immobilityFear of asphyxiationWeight lossExhaustionShortness of breathLimitations in the exercise of professionFear of deathConcern regarding availability of an organ in case of transplantationLoss of appetiteConcentration disturbancePhlegmLimitation in the practice of hobbiesAnxiety in generalDifficulties in thinking and problem solvingSputum when coughingActivity limitation due to respiratory problemsEmotional problemsSleepinessRespiratory distressDepressionGeneral fatigueJaundice of the eyesDaytime sleepinessJaundice of the skin Summary of relevant quality of life domains and aspects selected by experts Systematic search for PROMs Literature search I: PROMs specifically developed for AATD patients In July 2021, the questionnaire databases PROQOLID, Hogrefe Testzentrale, Open Test Archive and Registry of Scales and Measures were searched for AATD-specific PROMs by a statistician with methodical expertise (KM). Only a single concept, “AATD” was used. The search was adapted for several synonyms, such as “α1-antitrypsin deficiency”, “alpha 1-antitrypsin deficiency”, “alpha-1 antitrypsin deficiency” and “alpha-1-antitrypsin deficiency”. Literature search II: PROMs used in AATD patients In July 2021, searches in electronic bibliographic databases (MEDLINE (Ovid), Embase (Ovid), Science Citation Index Expanded & Social Sciences Citation Index (Web of Science), APA PsycInfo (EBSCOhost), CINAHL (EBSCOhost), COSMIN Database of Systematic Reviews and Cochrane Library (Wiley)), the web search engine Google Scholar (first 100 results) and trial registers for ongoing and recently completed trials (ClinicalTrials.gov and EU CTR) were carried out in accordance with COSMIN and Peer Review of Electronic Search Strategies (PRESS) guidelines.8 12 As a deviation from the protocol, WHO ICTRP was not searched as the platform was not in a fully functional state at that time. Complete and reproducible search strategies and Preferred Reporting Items for Systematic Reviews and Meta-Analyses – Search Extension (PRISMA-S) checklist are available.14 An initial search strategy for MEDLINE was created by a librarian with expertise in searching for systematic reviews (HK) and peer-reviewed by an independent librarian (BD). This strategy was then adopted to the other databases. No limits regarding study design, date or language were used. Additionally, the reference lists of included primary studies and relevant published reviews, as well as the authors’ personal files, were used as sources of information by the reviewers (KM and LV). Literature search III: PROMs used in patients with lung or liver disease As lung and liver disease are the most common clinical sequelae of AATD,2 the COSMIN database of systematic reviews of outcome measurement instruments was searched by KM in January 2022 for reviews of PROMs used in patients with “lung disease” and “liver disease” to identify potentially relevant PROMs for AATD patients. Screening records Abstract screening and preparing full texts Two reviewers (KM and LV) independently screened the titles and abstracts of all records (including primary studies, reviews, position papers, abstracts, trials) identified by the searches, with a focus on whether the records contained the target concepts AATD patients and PROM. Next, full texts of all records that included these target concepts were obtained. Full texts were excluded if any of the exclusion criteria applied: duplicate, previous version of a record, no adequate translation by using Google Translate or DeepL Translator could be carried out, no full text of the record could be requested, no AATD topic was addressed and the record did not capture the target concept (AATD patients and PROM). Disagreement regarding the eligibility of specific records was discussed by the reviewers (KM and LV) and resolved by consensus. If consensus could not be obtained, a third reviewer was involved (MK). The number of records at each stage of the search and the reasons for excluding records were recorded. None of the reviewers was blinded to the journal titles, the study authors or the institutions. Full text screening The reviewers (KM and LV) independently read the full texts of the remaining records and identified the use of PROMs in the context of AATD patients. The numbers of identified generic, lung-specific and liver-specific PROMs were recorded. Selecting PROMs PROM eligibility assessment KM and LV independently screened the identified PROMs and excluded PROMs that did not meet the predefined basic eligibility criteria13 and relevant QoL domains (table 1). Disagreement regarding the eligibility of PROMs was discussed by the reviewers (KM and LV) and resolved by consensus. If consensus could not be reached, a third reviewer was involved (MK). Study group consensus The study group consisted of clinical AATD experts (RB, TG, CV, FL and PS), a representative of a patient organisation (MW) and methodological experts (MK and KM). Based on the findings of the literature search and the clinical perspective with regard to an adequate PROM, the group discussed various options and came to a final decision by group consensus.11 Data management All records identified in database searches were compiled in Citavi. Duplicates were removed in Endnote using the method of Bramer et al.15 Review documentation was compiled in the free web tool Rayyan (www.rayyan.ai) and Microsoft Excel. Review documentation in Rayyan was stored on cloud services and automatically backed up daily. Review documentation, search results studies and relevant PROMs were saved and backed up on the institute’s own data server. Data were only accessed by the reviewers (KM, LV and MK). RESULTS Overview Figure 1 represents an overview of the literature search and the identification and selection process. The literature search process yielded a total of N=2045 records. After removing duplicates, n=1255 records were screened for the target concepts AATD patients and PROM. In the resulting n=191 records, 427 PROMs were identified. Different versions of PROMs (eg, 36-Item Short Form Health Survey (SF-36) and 12-Item Short Form Health Survey (SF-12) or EuroQoL 5 Dimension 3 Level (EQ-5D-3L) and EuroQoL 5 Dimension 5 Level (EQ-5D-5L)) as well as usage of single or all subscales of a PROM (eg, EuroQol Visual Analogue Scale (EQ VAS) and/or EuroQol Health Utility Index (EQ Index)) in a record were combined into one hit. Eligibility assessment of the 427 PROMs resulted in a total of 15 eligible PROMs. Information about screened records and the eligibility assessment of hits is available.14 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. AATD, alpha-1-antitrypsin deficiency; BCSS, Breathlessness, Cough and Sputum Scale; CAT, COPD Assessment Test; CLDQ, Chronic Liver Disease Quality of Life; COSMIN, COsensus-based Standards for the selection of health Measurement INstruments; CRQ, Chronic Respiratory Disease Questionnaire; EQ-5D-5L, EuroQoL 5 Dimension 5 Level; FACT-G, Functional Assessment of Cancer Therapy-General; MSAS-SF, Memorial Symptom Assessment Scale-Short Form; NHP, Nottingham Health Profile; PGWBI, Psychological General Well-Being Index; PLC, Profil der Lebensqualität Chronisch Kranker; PQLS, Pulmonary-Specific Quality of Life Scale; PROM, patient-reported outcome measure; QoL, quality of life; QOL-B, Quality of Life Questionnaire Bronchiectasis; SGRQ, St. George Respiratory Questionnaire. Literature search I: PROMs specifically developed for AATD patients Comprehensive literature search I did not identify a single questionnaire that was specifically developed for AATD patients. Literature search II: PROMs used in AATD patients In total, 48 PROMs were identified that had been used for outcome assessment in patients with AATD. Of these, n=11 could be labelled ‘generic’, n=16 ‘lung-specific’, n=1 ‘liver-specific’ and n=20 ‘other’ (eg, Oral Health Impact Profile-14). Additionally, in ten records, no standardised questions were used and in six records, a specific PROM was not named. Literature search III: PROMs used in patients with lung or liver disease 28 of the 48 identified PROMs in literature search II were also identified in literature search III. Additionally, 379 PROMs were identified that had been used for outcome assessment in patients with lung or liver disease. Of these, n=196 could be labelled ‘generic’, n=60 ‘lung-specific’, n=4 ‘liver-specific’ and n=119 ‘other disease specific’ (eg, Inflammatory Bowel Disease Questionnaire). Eligibility assessment and preselection of PROMs used in AATD patients: creating a short list The identified 427 PROMs were compared with basic eligibility criteria and content criteria specified by the experts. As a result, 412 questionnaires were omitted due to the following reasons: n=266 were not or partially not relevant in terms of content. n=266 were not or partially not relevant in terms of content. n=53 were not available in German. n=53 were not available in German. n=74 did only address one relevant QoL dimension, n=74 did only address one relevant QoL dimension, n=19 other reasons (not for adults, interviewer administered, too many items, not standardised (single) items, fees/conflicting information on licence costs). n=19 other reasons (not for adults, interviewer administered, too many items, not standardised (single) items, fees/conflicting information on licence costs). The exclusions were consented to by AATD experts, resulting in a short list of 15 PROMs (table 2): Table 2Preselected PROMsPROMNumber of itemsDomainsScoresCompleting timePaper-based/electronicRecall periodLanguagesGeneric PROMsCOOP/WONCA charts66: physical fitness, feelings, daily activities, social activities, change in health, overall health6: physical fitness, feelings, daily activities, social activities, change in health, overall health<5 minPaper-based2 weeksGerman, English+19 translationsEuroQoL 5-Dimension 5-Level (EQ-5D-5L)66: mobility, self-care, usual activities, pain/discomfort, anxiety/depression, general state of health7: mobility score, self-care, usual activities, pain/discomfort, anxiety/depression, EQ Index, EQ VAS<5 minPaper-based/electronictodayGerman, English+206 translationsFunctional Assessment of Cancer Therapy-General (FACT-G)274: physical, social/family, emotional, functional well-being4: physical, social/family, emotional, functional well-being5–10 minPaper-based/electronic1 weekGerman, English+76 translationsMemorial Symptom Assessment Scale-Short Form (MSAS-SF)322: physical symptoms, psychological symptoms3: global distress index, physical symptom distress score, psychological symptom distress score10–15 minPaper-based1 weekGerman, English+5 translationsNottingham Health Profile (NHP)456: sleep, physical mobility, energy, pain, emotional reactions, social isolation+life areas affected6: sleep, physical mobility, energy, pain, emotional reactions, social isolation>15 minPaper-basedNo specific recall periodGerman, English+27 translationsProfile der Lebensqualität Chronisch Kranker (Profiles of Quality of Life with Chronic Disease) (PLC)406: physical, psychological and social capacity of performance and well-being6: physical, psychological and social capacity of performance and well-being>15 minPaper based1 weekGerman, SpanishPsychological General Well-Being Index (PGWBI)226: anxiety, depression, positive well-being, self-control, general health, vitality7: anxiety, depression, positive well-being, self-control, general health, vitality, total score5–10 minPaper-based1 week or 1 monthGerman, English+38 translationsLung-specific PROMsBreathlessness, Cough and Sputum Scale (BCSS)33: breathlessness, cough, sputum3: breathlessness, cough, sputum<5 minPaper-basedTodayGerman, English 25 translationsChronic Respiratory Disease Questionnaire (CRQ)204: dyspnoea, fatigue, emotional function, mastery of breathlessness5: dyspnoea, fatigue, emotional functioning, mastery of breathlessness, total score10–15 minPaper-based2 weeksGerman, English+19 translationsClinical COPD Questionnaire (CCQ)103: symptoms (dyspnoea, cough, phlegm), functional state (daily activities), mental state (depressed, concerns about breathing)4: symptoms, functional, mental, total score<5 minPaper-based/electronic1 day or 1 weekGerman, English+70 translationsCOPD Assessment Test (CAT)8cough, phlegm (mucus) in chest, tightness in chest, breathlessness, limited in activities, doubts, sleeping problems, energy1: total score<5 minPaper-based/electronicNo specific recall periodGerman, English+60 translationsPulmonary-Specific Quality of Life Scale (PQLS)253: task interference, physical, psychological,4: task interference, physical, psychological, total score10–15 minPaper-based1 monthGerman, EnglishQuality of Life Questionnaire Bronchiectasis (QOL-B Version 3.1)378: respiratory symptoms, physical functioning, vitality, role functioning, health perceptions, emotional functioning, social functioning, treatment burden8: respiratory symptoms, physical functioning, vitality, role functioning, health perceptions, emotional functioning, social functioning, treatment burden10–15 minPaper-based1 weekGerman, English+44 translationsSt. George Respiratory Questionnaire (SGRQ)503: symptom score, activity score, impacts score4: symptoms, activity, impacts, total score>15 minPaper-based1, 3 or 12 monthsGerman, English+185 translationsLiver-specific PROMsChronic Liver Disease Quality of Life (CLDQ)296: fatigue, activity, emotional function, abdominal symptoms, systemic symptoms, worry7: fatigue, activity, emotional function, abdominal symptoms, systemic symptoms, worry, overall score10–15 minPaper-based2 weeksGerman, English+97 translationsEQ Index, EuroQol Health Utility Index; EQ VAS, EuroQol Visual Analogue Scale; PROM, patient-reported outcome measure. Preselected PROMs EQ Index, EuroQol Health Utility Index; EQ VAS, EuroQol Visual Analogue Scale; PROM, patient-reported outcome measure. Generic=COOP/WONCA charts,16 EQ-5D-5L,17 Functional Assessment of Cancer Therapy-General (FACT-G),18 Memorial Symptom Assessment Scale-Short Form (MSAS-SF),19 Nottingham Health Profile (NHP),20 Profil der Lebensqualität Chronisch Kranker (Profile of Quality of Life with Chronic Disease) (PLC),21 Psychological General Well-Being Index (PGWBI).22 Generic=COOP/WONCA charts,16 EQ-5D-5L,17 Functional Assessment of Cancer Therapy-General (FACT-G),18 Memorial Symptom Assessment Scale-Short Form (MSAS-SF),19 Nottingham Health Profile (NHP),20 Profil der Lebensqualität Chronisch Kranker (Profile of Quality of Life with Chronic Disease) (PLC),21 Psychological General Well-Being Index (PGWBI).22 Lung-specific=Breathlessness, Cough and Sputum Scale (BCSS),23 Chronic Respiratory Disease Questionnaire (CRQ),24 Clinical COPD Questionnaire (CCQ),25 COPD Assessment Test (CAT),26 Pulmonary-Specific Quality of Life Scale (PQLS),27 Quality of Life Questionnaire Bronchiectasis (QOL-B),28 St. George Respiratory Questionnaire (SGRQ).29 Lung-specific=Breathlessness, Cough and Sputum Scale (BCSS),23 Chronic Respiratory Disease Questionnaire (CRQ),24 Clinical COPD Questionnaire (CCQ),25 COPD Assessment Test (CAT),26 Pulmonary-Specific Quality of Life Scale (PQLS),27 Quality of Life Questionnaire Bronchiectasis (QOL-B),28 St. George Respiratory Questionnaire (SGRQ).29 Liver-specific=Chronic Liver Disease Quality of Life (CLDQ).30 Liver-specific=Chronic Liver Disease Quality of Life (CLDQ).30 Expert consensus: reasons for selecting PROMs from the short list Generic PROM The group agreed to select the widely used EQ-5D-5L because of its brevity, availability of normative data and suitability for health-economic evaluations.17 PROMs measuring general QoL are less sensitive to map changes than disease-specific QoL.31,33 The SF-12 would have been an alternative candidate that also shared these positive characteristics but was discarded at an earlier stage mainly due to conflicting information on licensing and cost issues. The COOP-WONCA is easy to use with a short administration time, but it was rarely used in patients with COPD34 and chronic liver disease.35 The PGWB has been used in patients with mild asthma,36 but there is little information on the development of the questionnaire and its factor structure. The MSAS-SF is longer than the EQ-5D-5L, and there remains uncertainty about the degree of developmental maturity of the questionnaire (unclear which version is recommended). Furthermore, it does not distinguish between moderate and severe COPD.37 Although FACT-G was developed for cancer patients, it assesses QoL in a general manner without referencing any specific disease.18 However, the FACT-G, NHP and PLC are longer than the EQ-5D-5L. Besides the length, the NHP is less used nowadays, and the PLC is only available in German. The EQ-5D-5L consists of six variables.17 The five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) are assessed on a 5-point Likert scale and can be combined into an EQ Index ranging from −0.661 (worst health state) to 1.000 (best health state). Additionally, the questionnaire consists of a VAS, ranging from 0 (worst health) to 100 (best health). In the context of COPD, a minimal clinically important difference of 8 score points on the EQ VAS was determined.38 QoL of patients with COPD without AATD and patients with COPD with AATD is comparable with or without augmentation therapy.39 40 Lung-specific PROM After considering the properties of the various questionnaires and discussing them in the group, the CAT turned out to be the most adequate questionnaire for the present purposes. The CAT was developed to measure the impact of COPD on patients’ health and is intended to complement clinical assessments such as forced expiratory volume.26 The questionnaire consists of eight variables assessed on a 6-point Likert scale. The summary score ranges from 0 to 40, while higher scores indicate a higher impact of COPD on well-being: 0–9 low, 10–20 medium, 21–30 high, 31–40 very high impact. The SGRQ is the most frequently used lung-specific PROM (table 2), but also the longest questionnaire (depending on the version 40–76 items). The CAT has similar properties to the more complex SGRQ.26 41 42 Previous studies have shown that the CAT correlates highly with the SGRQ, while the CAT is easier and faster to complete.42,46 In addition, patients as well as researchers rate the CAT as easier and faster to use than the SGRQ.26 The CCQ was developed for patients with COPD and resembles numerous features of the CAT.25 Both the CCQ and the CAT are comparable in terms of short completion time, ease of completion and score calculation, psychometric properties, the ability to predict mortality, the high importance of information for healthcare providers in clinical routine and good acceptability by the patients.2547,49 The CCQ and the CAT also show a clinically relevant change between exacerbation and recovery.50 A minimal important difference criterion is defined for the CCQ.49 51 However, it does not distinguish between repeated measurement error at the group level and at the individual level.52 On the other hand, the minimal important difference defined for the CAT (1– 3.8 points) can be distinguished from repeated measurement error at the group level.52 In summary, the CAT was favoured over the CCQ as the CAT has been used in AATD patients and is more suitable for measuring changes in respiratory symptoms. The PQLS was developed for patients with end-stage lung disease who are awaiting a lung transplant. However, the questionnaire has been rarely used and never in patients with AATD. Besides the rare usage and sometimes lack of tests of psychometric properties, the PQLS has more items than the favoured CAT. The QoL-B was developed for patients with bronchiectasis and has shown sufficient content validity of high quality and good psychometric data.28 38 53 The CRQ was developed for patients with chronic airflow limitations.54 55 Due to their rare usage in AATD patients and a higher number of items, QoL-B and CRQ are less favoured than CAT. The BCSS was developed for patients with COPD23 and was never used in patients with AATD. It is a 3-item short PROM assessing the severity of breathlessness, cough and sputum. Although BCSS is shorter than CAT, CAT incorporates more relevant QoL aspects. Liver-specific PROM For liver-specific PROM, only one questionnaire with good psychometric properties was available: CLDQ,56 and more specifically the validated and linguistically adapted German version CLDQ-D.30 The CLDQ was developed for patients with chronic liver diseases and consists of 29 items assessed on a seven-point Likert scale. The CLDQ covers six sub-scores (fatigue, activity, emotional function, abdominal symptoms, systemic symptoms, worry) and an overall score.56 The criteria for content validity were rated as sufficient and the quality of the evidence as high, although the CLDQ was not developed for AATD patients and not all methodical details were clearly addressed in the original manuscript.56 Each CLDQ score ranges from 1 to 7 with higher scores indicating better QoL.30 A difference of 0.5 in CLDQ scores is considered a minimal clinically important difference.56 According to the German scoring information regarding repeated measures, differences of 0.8 are clinically relevant for individual analyses and deviations of ≥0.5 SD for group analyses. CLDQ scores are responsive to change, as shown in studies on liver transplantation.56 57 Summary of the selection process and additional questions In a standardised group process including information about preliminary psychometric properties, three PROMs with high content validity and feasibility in clinical routine as well as clinical studies (eg, shortness, comprehensibility) were selected for a modular approach assessing QoL in AATD patients: EQ-5D-5L (generic), CAT (lung-specific) and CLDQ (liver-specific). These questionnaires cover predefined relevant QoL domains (table 1). This group decision was unanimous (100% group consensus). In addition, relevant QoL issues/aspects that were not addressed by the three selected PROMs were included: concerns regarding the availability of a suitable organ in the event of a lung transplant, feeling joy of life, going to lung sports, receiving psychological treatment, need for psychological support and feeling informed about AATD. Moreover, sociodemographic and health-related questions were added to the designed questionnaire: sex, age, height, weight, highest education, current employment status, year of AATD diagnosis, AATD type, AATD organ manifestation, laboratory parameters, substitution, need for oxygen treatment, transplantation, comorbidities, current health status (modified Karnofsky performance status scale) and degree of disability. This objective supplementary information is necessary to complement subjective data. Figure 2 illustrates the final PROM that we consider for further use in AATD patients and propose to name ALPHA (Assessment of Lung, Liver and Patient Health in Alpha-1). ALPHA (Assessment of Lung, Liver and Patient Health in Alpha-1): the patient-reported outcome measure designed for patients with alpha-1 antitrypsin deficiency. Discussion The past two decades have witnessed an ever-growing literature on PROMs.6 The database PROQOLID (https://eprovide.mapi-trust.org) compiles more than 6000 PROMs, and the number continues to grow. Therefore, instead of developing and validating a new questionnaire for the research project of interest, one should take advantage of one or more of the existing validated PROMs.6 If necessary, appropriate candidates may be amended to fit the target population and setting. Care must be taken to ensure that any modifications do not violate the content and psychometric criteria of the original questionnaire. Whereas PROMs are designed to assess patients’ subject health perception, the documentation of objective clinical data will provide a comprehensive view of a patient’s health status. Up to now, no accepted and validated measurement approach has existed that addresses QoL issues of patients with AATD. To select appropriate PROMs for use in patients with AATD, a step-by-step process was applied. In literature searches, over 1200 records were identified and screened. Within standardised group processes, crucial eligibility criteria were defined, and a modular approach to assessing generic, lung-specific and liver-specific QoL was agreed on. In total, 247 PROMs were identified and assessed for eligibility. 15 out of 247 PROMs fulfilled predefined eligibility criteria. Most PROMs had satisfactory psychometric properties. The selection of the final three PROMs was based on the following aspects: content and clinical appropriateness, brevity, easy usage and interpretation, availability of minimal clinically important differences, sensitivity to change, possibility to distinguish between disease severity and availability of reference data. The three selected PROMS assess generic (EQ-5D-5L), lung-specific (CAT) and liver-specific (CLDQ) aspects of QoL. A short set of self-developed items at the very end of the questionnaire examines treatment-related aspects of QoL as well as basic sociodemographic and objective health criteria. AATD may affect different organ systems, most commonly the lungs and liver. Depending on genotype, comorbidity, lifestyle and age, there are also cases with lung and liver symptoms presenting simultaneously. To address these major disease manifestations, the ALPHA instrument was designed as a modular tool that allows the assessment of QoL domains relevant to the individual patient’s clinical presentation. This flexible structure enables the use of generic and organ-specific components according to disease involvement and will be further examined in the forthcoming validation study. Based on this conceptual framework, the selected PROMs were combined to form the ALPHA instrument while maintaining the scoring of each questionnaire. No summary score or weighted scores will be calculated, as the instruments address distinct dimensions of QoL. This approach preserves conceptual clarity and allows for comparability with published reference values. The questionnaire assembled through this combined systematic review and consensus-based approach holds potential value for both clinical practice and research in patients with AATD. In clinical settings, the modular approach combining generic (EQ-5D-5L), lung-specific (CAT) and liver-specific (CLDQ) measures allows for a comprehensive assessment of QoL across multiple domains relevant to AATD patients, which helps monitor PRO over time, guide treatment decisions and identify areas requiring medical attention. For research purposes, the standardised and validated nature of the selected instruments allows for consistent data collection across studies, facilitating comparisons and meta-analyses. While we recognise that the sole use of the EQ-5D-5L is unlikely to fully capture treatment-related changes in QoL,33 the lung- and liver-specific questionnaires address the very symptoms at the core of healthcare. A potential limitation of the present manuscript may be the lack of a fully flagged presentation of the evaluation of preselected questionnaires according to the COSMIN checklist. Because our initial review of the literature suggested that comprehensive psychometric evaluations of the questionnaires for AATD patients were not to be expected due to the rarity of the disease, we used a pragmatic two-step research approach. First, we searched for potential questionnaire candidates that assessed QoL contents of clinical interest, and second, we determined the psychometric properties of these candidates in a subsequent set of prospective studies. According to this project plan, follow-up papers will report on these studies and the psychometric findings. Another limitation concerns the exclusion of questionnaires without an available German translation. While this may restrict generalisability, focusing on German-language instruments ensured linguistic and cultural applicability within the intended clinical context. Automated translations were not considered appropriate, as the use of PROMs requires standardised forward–backward translation and cross-cultural validation procedures according to established guidelines.58 All identified instruments, including reasons for exclusion, are provided in the open-access dataset.14 The selected PROMs (EQ-5D-5L, CAT and CLDQ) are internationally established instruments available in major languages, including English, German, Spanish and Chinese, ensuring broad applicability and comparability across studies. Conclusions The research group agreed on a modular approach that covered relevant generic, lung-specific and liver-specific QOL aspects. Three appropriate PROMs (EQ-5D-5L, CAT, CLDQ) were selected. These PROMs were supplemented by relevant QoL issues not addressed otherwise. An additional pair of studies will provide information on the psychometric properties of the selected questionnaires in AATD patients and their feasibility in clinical routine. Acknowledgements We thank Brigitte Doß, University Library, University of Regensburg, for the peer review of the search strategy for the systematic review and Monika Schöll, Center for Clinical Studies, University Hospital Regensburg, for the linguistic revision of the manuscript. Footnotes Funding: The systematic review and selecting of adequate PROM for assessing QoL in patients with AATD is part of a larger project. The project was financially supported by CSL Behring GmbH. The funder had no role in the design and conduct of the study. Data availability free text: Data supporting this study is available via open-access publication server of the University of Regensburg (Müller K, Vogl L, Knüttel H, Greulich T, Lammert F, Strnad P et al. Supporting Data for the Manuscript "Patient-related outcome measures for use in patients with alpha-1-antitrypsin deficiency: Results of a systematic selection process"; 2025. doi: 10.5283/epub.76669). Patient consent for publication: Not applicable. Ethics approval: Not applicable. Provenance and peer review: Not commissioned; externally peer reviewed. Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. Data availability statement Data are available in a public, open access repository. Data are available upon reasonable request. References Associated Data Data Availability Statement Data are available in a public, open access repository. Data are available upon reasonable request.